---
input_text: 'Neural transplantation in Huntington disease: long-term grafts in two
  patients. OBJECTIVE: Clinical trials of fetal neural tissue transplantation for
  Huntington disease (HD) have been conducted with variable clinical results. However,
  no long-term analysis of graft survival and integration has been published. Here,
  we report the pathologic findings in two patients with HD who died 74 and 79 months
  after transplantation. METHODS: Methods used were pathologic examination, histochemistry,
  and immunohistochemistry. RESULTS: Neostriatum from both patients showed typical
  neuropathologic changes of advanced HD. Surviving grafts were identified in both
  patients (6/6 sites and 7/8 sites, respectively) as well-demarcated nests within
  host neostriatum with associated needle tracts. Grafted neurons adopted either dominant
  calbindin/parvalbumin or calretinin immunoreactivity (IR). Few neurofilament, MAP-2,
  DARPP-32, tyrosine hydroxylase, or calbindin IR processes traversed the host parenchyma-graft
  interface despite minimal junctional gliosis. Immunohistochemistry for CD68 showed
  microgliosis that was more pronounced in host striatum than graft. Scattered CD45
  and CD3 IR cells were present within grafts and host parenchyma. No ubiquitin IR
  neuronal intranuclear inclusions were identified in graft neurons, although these
  were prevalent in host cells. CONCLUSIONS: These two autopsies confirm previous
  findings of neuronal differentiation and survival of transplanted fetal tissue from
  the ganglionic eminence and also demonstrate viability of neurons from fetal transplants
  in human neostriatum for more than 6 years. Despite prolonged survival, these grafts
  had poor integration with host striatum that is likely responsible for lack of clear
  clinical improvement in these patients.'
raw_completion_output: |-
  primary_disease: Huntington disease

  medical_actions: neural transplantation; pathologic examination; histochemistry; immunohistochemistry

  symptoms: neuropathologic changes; microgliosis

  chemicals: calbindin; parvalbumin; calretinin; neurofilament; MAP-2; DARPP-32; tyrosine hydroxylase; CD68; CD45; CD3; ubiquitin

  action_annotation_relationships: neural transplantation TREATS neuropathologic changes IN Huntington disease; pathologic examination ASSESSES neuropathologic changes IN Huntington disease; histochemistry ASSESSES neuropathologic changes IN Huntington disease; immunohistochemistry (with calbindin, parvalbumin, calretinin, neurofilament, MAP-2, DARPP-32, tyrosine hydroxylase, CD68, CD45, CD3, ubiquitin) ASSESSES neuropathologic changes IN Huntington disease; immunohistochemistry (with CD68) ASSESSES microgliosis IN Huntington disease
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  immunohistochemistry (with CD68) ASSESSES microgliosis IN Huntington disease

  ===

extracted_object:
  primary_disease: MONDO:0007739
  medical_actions:
    - neural transplantation
    - pathologic examination
    - histochemistry
    - immunohistochemistry
  symptoms:
    - neuropathologic changes
    - microgliosis
  chemicals:
    - calbindin
    - parvalbumin
    - calretinin
    - neurofilament
    - MAP-2
    - DARPP-32
    - tyrosine hydroxylase
    - CD68
    - CD45
    - CD3
    - ubiquitin
  action_annotation_relationships:
    - subject: neural transplantation
      predicate: TREATS
      object: neuropathologic changes
      qualifier: MONDO:0007739
    - subject: pathologic examination
      predicate: ASSESSES
      object: neuropathologic changes
      qualifier: MONDO:0007739
    - subject: histochemistry
      predicate: ASSESSES
      object: neuropathologic changes
      qualifier: MONDO:0007739
    - subject: <immunohistochemistry>
      predicate: <ASSESSES>
      object: <neuropathologic changes>
      qualifier: <Huntington disease>
      subject_qualifier: <with calbindin, parvalbumin, calretinin, neurofilament,
        MAP-2, DARPP-32, tyrosine hydroxylase, CD68, CD45, CD3, ubiquitin>
      subject_extension: <calbindin, parvalbumin, calretinin, neurofilament, MAP-2,
        DARPP-32, tyrosine hydroxylase, CD68, CD45, CD3, ubiquitin>
    - subject: <immunohistochemistry>
      predicate: <ASSESSES>
      object: <microgliosis>
      qualifier: <Huntington disease>
      subject_qualifier: <with CD68>
      subject_extension: <CD68>
named_entities:
  - id: MONDO:0007739
    label: Huntington disease
  - id: MAXO:0001298
    label: therapy
  - id: HP:0002180
    label: neurodegeneration
  - id: HP:0001268
    label: cognitive decline
  - id: HP:0100022
    label: movement disorders
  - id: HP:0002072
    label: choreic movements
  - id: MAXO:0009003
    label: preimplantation genetic testing
  - id: MAXO:0001592
    label: RNA interference therapy
  - id: HP:0000716
    label: depression
  - id: HP:0000739
    label: anxiety
  - id: HP:0000737
    label: irritability
  - id: CHEBI:7735
    label: olanzapine
  - id: MAXO:0000882
    label: behavioral interventions
  - id: HP:0004395
    label: malnutrition
  - id: MAXO:0000011
    label: physical therapy
  - id: CHEBI:22720
    label: benzodiazepines
  - id: CHEBI:2618
    label: amantadine
  - id: CHEBI:15765
    label: levodopa
  - id: HP:0002315
    label: Headache
  - id: CHEBI:134738
    label: Laquinimod
  - id: CHEBI:4903
    label: Ethinylestradiol
  - id: CHEBI:6443
    label: Levonorgestrel
  - id: HP:0001251
    label: Ataxia
  - id: HP:0001260
    label: Dysarthria
  - id: HP:0002119
    label: Ventricular dilatation
  - id: HP:0100543
    label: cognitive deficits
  - id: HP:0000708
    label: Behavioral changes
  - id: CHEBI:92976
    label: Latrepirdine
  - id: MONDO:0005559
    label: Neurodegenerative diseases
  - id: CHEBI:16243
    label: Quercetin
  - id: CHEBI:3962
    label: Curcumin
  - id: CHEBI:27881
    label: Resveratrol
  - id: CHEBI:75095
    label: Chrysin
  - id: CHEBI:28821
    label: Piperine
  - id: CHEBI:17620
    label: Ferulic acid
  - id: CHEBI:78330
    label: Huperzine A
  - id: CHEBI:16118
    label: Berberine
  - id: CHEBI:2979
    label: Baicalein
  - id: CHEBI:28230
    label: Hesperetin
  - id: CHEBI:26536
    label: Retinoic acid
  - id: MAXO:0000127
    label: Genetic testing
  - id: CHEBI:76004
    label: Dimethyl fumarate
  - id: MAXO:0010012
    label: coenzyme Q10 supplementation
  - id: HP:0003287
    label: mitochondrial dysfunction
  - id: HP:0025464
    label: oxidative stress
  - id: CHEBI:46245
    label: coenzyme Q10
  - id: CHEBI:31687
    label: idebenone
  - id: MONDO:0100339
    label: Friedreich ataxia
  - id: MONDO:0016621
    label: Juvenile Huntington Disease
  - id: MAXO:0000021
    label: Palliative care
  - id: CHEBI:6030
    label: Isoniazid (INH)
  - id: CHEBI:16865
    label: gamma-aminobutyric acid (GABA)
  - id: HP:0000709
    label: psychosis
  - id: HP:0011951
    label: aspiration pneumonia
  - id: MAXO:0000065
    label: aerobic exercises
  - id: MAXO:0000487
    label: clinical assessments
  - id: MAXO:0000387
    label: muscle biopsy
  - id: CHEBI:9467
    label: Tetrabenazine
  - id: MAXO:0000943
    label: Deep brain stimulation
  - id: HP:0001332
    label: Dystonia
  - id: HP:0001336
    label: Myoclonus
  - id: HP:0100033
    label: Tics
  - id: HP:0001300
    label: Parkinsonism
  - id: CHEBI:35469
    label: Antidepressants
  - id: CHEBI:51373
    label: GABA agonists
  - id: CHEBI:38462
    label: Acetylcholinesterase inhibitors
  - id: MONDO:0005071
    label: Neurological disorders
  - id: MAXO:0001001
    label: Gene therapy
  - id: HP:0033429
    label: neuroinflammation
  - id: MAXO:0000079
    label: genetic counseling
  - id: MAXO:0000016
    label: Cell Therapy
  - id: MONDO:0008199
    label: Parkinson Disease (PD) and Huntington Disease (HD)
  - id: MONDO:0005314
    label: Relapsing-remitting multiple sclerosis (RRMS)
  - id: MAXO:0001394
    label: oral administration
  - id: MAXO:0001610
    label: repetitive transcranial magnetic stimulation (rTMS)
  - id: CHEBI:76720
    label: Antisense oligonucleotides
  - id: MONDO:0001516
    label: spinal muscular atrophy
